OR
Ortin Global Ltd (ORTINGLOBE)
₹12.37
Mkt cap
₹11 Cr
P/E ratio
—
P/B
16.06
Div yield
0.00%
ROE
−48.40%
ROCE
−33.90%
EPS (TTM)
—
Book value
₹1
52W range
11–21
Sector
Healthcare
Price history
Previous close
Incorporated in 1986, Ortin Laboratories Ltd manufactures pharmaceutical formulations. [1]
NSE ORTINGLOBEBSE 539287
Health check
Cautious
ProfitabilityWeak
GrowthLow
TechnicalsBearish
52-week range
−41.92% from high₹12
₹11+12.45% from low₹21
Current
₹12.37
Prev close
₹12.42
Day
−0.40%
Price performance
1D
+2.82%
1W
−1.24%
1M
−4.13%
3M
−19.94%
6M
−18.14%
1Y
+11.24%
YTD
−12.58%
Financials
Revenue, profit & margin
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.27 | 0.14 | 0.30 | 0.21 | 0.05 | 0.03 | 0.09 | 0.08 | 0.01 | 0.01 | 0.30 | 0.01 | 0.04 | |
| YoY Sales growth | -65.82% | -88.03% | -79.87% | -86.62% | -81.48% | -78.57% | -70.00% | -61.90% | -80.00% | -66.67% | +233.33% | -87.50% | +300.00% | |
| Expenses | 1.17 | 2.74 | 3.35 | 0.31 | 0.50 | 0.16 | 0.25 | 0.24 | 0.51 | 0.06 | 0.31 | 0.34 | 0.31 | |
| Operating Profit | -0.90 | -2.60 | -3.05 | -0.10 | -0.45 | -0.13 | -0.16 | -0.16 | -0.50 | -0.05 | -0.01 | -0.33 | -0.27 | |
| OPM % | -333.33% | -1,857.14% | -1,016.67% | -47.62% | -900.00% | -433.33% | -177.78% | -200.00% | -5,000.00% | -500.00% | -3.33% | -3,300.00% | -675.00% | |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest | 0.15 | 0.14 | 0.08 | 0.00 | 0.02 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Depreciation | 0.06 | 0.06 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit before tax | -1.11 | -2.80 | -3.18 | -0.10 | -0.47 | -0.10 | -0.16 | -0.16 | -0.50 | -0.05 | -0.01 | -0.33 | -0.27 | |
| Tax % | 1.80% | -0.71% | 30.19% | 0.00% | 0.00% | 10.00% | 0.00% | 6.25% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Net Profit | -1.12 | -2.79 | -4.14 | -0.10 | -0.47 | -0.11 | -0.16 | -0.18 | -0.50 | -0.05 | -0.01 | -0.34 | -0.27 | |
| EPS in Rs | -1.38 | -3.43 | -5.09 | -0.12 | -0.58 | -0.14 | -0.20 | -0.22 | -0.61 | -0.06 | -0.01 | -0.42 | -0.33 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 20261.24%Promoter
Promoters1.24%0.01
FIIs0.67%1.13
Public98.09%1.13
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,880.00 | 36.66 | 4,51,075 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,442.00 | 88.89 | 3,03,749 | 0.26% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,670.00 | 81.82 | 1,77,632 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,424.00 | 97.75 | 1,30,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,189.90 | 26.20 | 1,18,693 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,380.00 | 41.17 | 1,15,267 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,391.80 | 36.21 | 1,12,442 | 0.93% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Ortin Global | ₹12.93 | — | 11 | 0.00% | 0 | +46.00% | 0 | +300.00% | −33.93% |
| Median: 160 Co. | ₹465.83 | 33.99 | 2,012 | 0.08% | 13 | +33.53% | 179 | +20.92% | 14.94% |
Filings
Annual reports15
Announcements5
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s 11 Nov - Board approved Q2/H1 FY27 unaudited results; Mathesh & Ramana resigned, S.D. Mehta & Co. appointed12 Nov 2026.Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors 11 Nov - Board approved Q2 FY27 results; auditor resigned 12 Nov 2026, S.D. Mehta & Co. appointed.Board Meeting Outcome for Outcome Of Board Meeting Held On 11.11.2026 11 Nov - Board approved Q2 FY2026-27 results; statutory auditor resigned and new auditor appointed, effective 12 November 2026.Results- Financial Results For Quarter And Half-Year Ended 30.09.2026 11 NovBoard Meeting Intimation for Meeting To Be Held On 11.11.2026. 5 Nov - Board meeting on 11 Nov 2026 to consider Q2 and half-year FY2026 results.






